Back to News
Feb 24, 2026 12:50 PM

These Analysts Slash Their Forecasts On GeneDx After Q4 Results

GeneDx Holdings Corp (NASDAQ:WGS) reported better-than-expected fourth-quarter financial results on Monday.

GeneDx reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $120.989 million which beat the analyst consensus estimate of $120.407 million.

GeneDx Holdings affirmed FY2026 sales guidance of $540.000 million to $555.000 million.

“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners, and our results demonstrate that. Our team is executing ...